{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:21:40Z","timestamp":1759159300281,"version":"3.40.5"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.<\/jats:p>","DOI":"10.61409\/v05240367","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:46:53Z","timestamp":1730900813000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation therapy for complex patient populations"],"prefix":"10.61409","author":[{"given":"Gro","family":"Egholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Steen","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Birgitte","family":"Lein\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn Dalsgaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja Hellfritzsch","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref0","unstructured":"Regionernes Kliniske Kvalitetsprogram. Databasen for atrieflimren i Danmark, \u00e5rsrapport 2023, 2023. https:\/\/www.sundhed.dk\/content\/cms\/45\/105045_afdk_aarsrapport_2023.pdf (27. aug 2024)."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"M\u00fcnster AM, Rasmussen TB, Falstie-Jensen AM et al. A changing landscape: temporal trends in incidens and characteristics of patients hospitalised with venous thromboembolism 2006-2015. Thromb Res. 2019;176:46-53. https:\/\/doi.org\/10.1016\/j.thromres.2019.02.009","DOI":"10.1016\/j.thromres.2019.02.009"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Poulsen MH, K\u00fcmler T, Lamberts MK et al. Direkte orale antikoagulantia til behandling af cancerassocieret trombose. Ugeskr L\u00e6ger 2024;186:V04240299. https:\/\/doi.org\/10.61409\/V05240367","DOI":"10.61409\/V05240367"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Hindley B, Lip GYH, McCloskey AP, Penson PE. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opin Drug Metab Toxicol. 2023;19(12):911-23. https:\/\/doi.org\/10.1080\/17425255.2023.2287472","DOI":"10.1080\/17425255.2023.2287472"},{"key":"ref4","unstructured":"Andersen L, Pareek M. Direkte orale antikoagulantia (DOAK), 2023. https:\/\/pro.medicin.dk\/Laegemiddelgrupper\/Grupper\/318642 (27. aug 2024)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Limdi NA, Limdi MA, Cavallari L et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56(5):823-31. https:\/\/doi.org\/10.1053\/j.ajkd.2010.05.023","DOI":"10.1053\/j.ajkd.2010.05.023"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Molnar AO, Bota SE, Garg AX et al. The risk of major hemorrhage with CKD. Journal of the American Society of Nephrology. 2016;27(9):2825-32. https:\/\/doi.org\/10.1681\/ASN.2015050535","DOI":"10.1681\/ASN.2015050535"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11):2662-8. https:\/\/doi.org\/10.2215\/cjn.04550511","DOI":"10.2215\/CJN.04550511"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Cho MS, Choi HO, Hwang KW et al. Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation. BMC Cardiovasc Disord. 2023;23(1):209. https:\/\/doi.org\/10.1186\/s12872-023-03236-5","DOI":"10.1186\/s12872-023-03236-5"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Steensig K, Pareek M, Krarup AL et al. Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - a nationwide register-based cohort study: thromboembolism and bleeding in liver disease. Clin Res Hepatol Gastroenterol. 2022;46(8):101952. https:\/\/doi.org\/10.1016\/j.clinre.2022.101952","DOI":"10.1016\/j.clinre.2022.101952"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 2018;71(19):2162-2175. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.023","DOI":"10.1016\/j.jacc.2018.03.023"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology. 2019;157(1):34-43.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.03.070","DOI":"10.1053\/j.gastro.2019.03.070"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-335. https:\/\/doi.org\/10.1002\/hep.28906","DOI":"10.1002\/hep.28906"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Rocca B, Fox KAA, Ajjan RA et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672-1686f. https:\/\/doi.org\/10.1093\/eurheartj\/ehy066","DOI":"10.1093\/eurheartj\/ehy066"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Mausteller KG, Eisele CD, Julian K et al. Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants. 2022;18(10):829-837. https:\/\/doi.org\/10.2217\/fca-2021-0146","DOI":"10.2217\/fca-2021-0146"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Elfar S, Mahmoud SA, Hamdi S et al. The safety and efficacy of nonvitamin K antagonist oral anticoagulants in morbidly obese patients with atrial fibrillation: a meta-analysis. BMC Cardiovasc Disord. 2024;24(1):74. https:\/\/doi.org\/10.1186\/s12872-024-03731-3","DOI":"10.1186\/s12872-024-03731-3"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Park DY, An S, Arif AW et al. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):100. https:\/\/doi.org\/10.1186\/s12872-023-03067-4","DOI":"10.1186\/s12872-023-03067-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874-1882. https:\/\/doi.org\/10.1111\/jth.15358","DOI":"10.1111\/jth.15358"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Steffel J, Collins R, Antz M et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612-1676. https:\/\/doi.org\/10.1093\/europace\/euab065","DOI":"10.1093\/europace\/euab065"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Serrao A, Lucani B, Mansour D et al. Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterr J Hematol Infect Dis. 2019;11(1):e2019044. https:\/\/doi.org\/10.4084\/MJHID.2019.044","DOI":"10.4084\/mjhid.2019.044"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Skeith L. Anticoagulating patients with high-risk acquired thrombophilias. Blood. 2018;132(21):2219-2229. https:\/\/doi.org\/10.1182\/blood-2018-05-848697","DOI":"10.1182\/blood-2018-05-848697"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019;171(10):685-694. https:\/\/doi.org\/10.7326\/m19-0291","DOI":"10.7326\/M19-0291"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Zuily S, Cohen H, Isenberg D et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(9):2126-2137. https:\/\/doi.org\/10.1111\/jth.14935","DOI":"10.1111\/jth.14935"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"den Exter PL, Woller SC, Robert-Ebadi H et al. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. J Thromb Haemost. 2022;20(8):1910-1919. https:\/\/doi.org\/10.1111\/jth.15776","DOI":"10.1111\/jth.15776"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Caso V, de Groot JR, Fernandez MS et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109(3):178-85. https:\/\/doi.org\/10.1136\/heartjnl-2022-321114","DOI":"10.1136\/heartjnl-2022-321114"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Swan D, Thachil J. Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis. J R Coll Physicians Edinb. 2022;52(4):341-349. https:\/\/doi.org\/10.1177\/14782715221134720","DOI":"10.1177\/14782715221134720"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Severinsen MT, Engebjerg MC, Farkas DK et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152(3):360-2. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08418.x","DOI":"10.1111\/j.1365-2141.2010.08418.x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"de Jong CMM, Blondon M, Ay C et al. Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism. Blood. 2022;142(16):1764-1773. https:\/\/doi.org\/10.1182\/blood.2022017101","DOI":"10.1182\/blood.2022017101"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"DeLoughery E, Bannow BS. Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation. Hematology Am Soc Hematol Educ Program. 2022;2022(1):467-473. https:\/\/doi.org\/10.1182\/hematology.2022000401","DOI":"10.1182\/hematology.2022000401"},{"key":"ref29","unstructured":"Hellfritzsch M, Hvas A-M, Dueholm M et al. Menorrhagia under antikoagulationsbehandling. Ugeskrift L\u00e6ger. 2020;182(49):V08200614. https:\/\/ugeskriftet.dk\/videnskab\/menoragi-under-antikoagulansbehandling (27. aug 2024)"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:58:05Z","timestamp":1747378685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V05240367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v05240367","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}